Home >> Top News >> Qiagen broadens GeneReader applications

Qiagen broadens GeneReader applications

Print Friendly, PDF & Email

July 27, 2018Qiagen has introduced next-generation sequencing solutions for a range of hereditary diseases on its GeneReader NGS System. The customizable QIAact target enrichment panels enable the analysis of more than 13 hereditary disease groups, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, and universal carrier screening. The solutions integrate the company’s QCI analysis, which includes the Human Gene Mutation Database, a knowledge base containing comprehensive data on inherited disease mutations for genetic and genomic research.

“Genetic laboratories are eager to gain deeper insights into a range of hereditary diseases by using the power of NGS technology but have been held back by the lack of complete workflows and powerful bioinformatics solutions,” Peer M. Schatz, CEO of Qiagen, said in a press release. “We are pleased to offer the first complete Sample to Insight solution for analysis of hereditary diseases. Our solution, anchored by the GeneReader NGS System, provides the complete solution that labs need to efficiently and reliably perform genetic analysis.”

More top news

x

Check Also

QIAscreen HPV PCR test launched in Europe

January 2019—Qiagen launched its QIAscreen HPV PCR Test, a CE-marked in vitro molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus. Validated sample types include cervical specimens collected in PreservCyt, Pathtezt, and Surepath collection medium, as well as self-collected vaginal brush specimens collected and shipped dry or in saline or self-collected cervico-vaginal lavage specimens.

X